| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
66,690 |
55,644 |
$2.34M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
28,063 |
25,733 |
$1.39M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
9,851 |
9,733 |
$764K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
8,799 |
8,632 |
$666K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
6,871 |
6,762 |
$564K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
49,490 |
18,549 |
$518K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
4,432 |
4,313 |
$386K |
| 99429 |
|
10,446 |
10,311 |
$333K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
6,650 |
6,381 |
$258K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
16,491 |
15,614 |
$218K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
11,613 |
7,303 |
$199K |
| 99381 |
|
2,452 |
2,367 |
$154K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
12,651 |
9,158 |
$101K |
| 87428 |
|
1,284 |
1,247 |
$89K |
| 69210 |
|
2,217 |
1,788 |
$81K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,025 |
998 |
$79K |
| 99442 |
|
2,085 |
1,982 |
$75K |
| 90461 |
|
19,573 |
12,095 |
$70K |
| 87807 |
|
5,639 |
5,374 |
$59K |
| 17110 |
|
692 |
661 |
$58K |
| 94010 |
|
2,009 |
1,857 |
$48K |
| 99383 |
|
510 |
500 |
$44K |
| 87634 |
|
765 |
743 |
$44K |
| 92551 |
|
7,121 |
7,001 |
$42K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,046 |
987 |
$38K |
| 99215 |
Prolong outpt/office vis |
477 |
461 |
$38K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
634 |
614 |
$35K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,371 |
1,349 |
$32K |
| 99382 |
|
292 |
283 |
$25K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,668 |
1,543 |
$24K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
459 |
439 |
$22K |
| 99000 |
|
1,866 |
1,780 |
$19K |
| 88720 |
|
4,913 |
2,935 |
$17K |
| 99050 |
|
1,058 |
993 |
$15K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,307 |
1,128 |
$14K |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
1,020 |
999 |
$13K |
| 99384 |
|
114 |
109 |
$10K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
90 |
86 |
$7K |
| 96160 |
|
4,154 |
3,976 |
$7K |
| 81002 |
|
2,448 |
2,313 |
$7K |
| 82947 |
|
1,691 |
1,638 |
$5K |
| 99441 |
|
209 |
202 |
$5K |
| 85018 |
|
2,874 |
2,798 |
$5K |
| 93000 |
|
275 |
269 |
$3K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
77 |
74 |
$2K |
| 92558 |
|
301 |
293 |
$2K |
| 80061 |
Lipid panel |
172 |
150 |
$2K |
| 86308 |
|
246 |
238 |
$1K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
914 |
860 |
$876.27 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
27 |
27 |
$344.83 |
| 69209 |
|
27 |
24 |
$339.66 |
| 81025 |
|
50 |
49 |
$333.70 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
1,790 |
1,655 |
$242.57 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
16 |
15 |
$209.44 |
| 99406 |
|
1,253 |
1,202 |
$96.72 |
| 83655 |
|
14 |
12 |
$50.85 |
| 99072 |
|
3,279 |
2,755 |
$44.40 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
93 |
77 |
$23.94 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
22 |
12 |
$18.24 |
| 90677 |
|
1,508 |
1,486 |
$1.85 |
| 90662 |
|
161 |
161 |
$1.03 |
| 90661 |
|
38 |
38 |
$0.06 |
| 90620 |
|
514 |
492 |
$0.02 |
| 90686 |
|
2,805 |
2,756 |
$0.02 |
| 90716 |
|
3,243 |
3,219 |
$0.01 |
| 90656 |
|
177 |
176 |
$0.01 |
| 90707 |
|
3,251 |
3,225 |
$0.01 |
| 90670 |
|
5,507 |
5,456 |
$0.01 |
| 90715 |
|
1,304 |
1,266 |
$0.01 |
| 90696 |
|
1,439 |
1,427 |
$0.00 |
| 90723 |
|
5,142 |
5,092 |
$0.00 |
| 96127 |
|
591 |
570 |
$0.00 |
| 90680 |
|
3,872 |
3,835 |
$0.00 |
| 90651 |
|
1,626 |
1,585 |
$0.00 |
| 90744 |
|
12 |
12 |
$0.00 |
| 90381 |
|
18 |
12 |
$0.00 |
| 90688 |
|
40 |
40 |
$0.00 |
| 99173 |
|
2,778 |
2,682 |
$0.00 |
| 90734 |
|
1,936 |
1,860 |
$0.00 |
| 90700 |
|
1,649 |
1,633 |
$0.00 |
| 99177 |
|
4,326 |
4,194 |
$0.00 |
| 90633 |
|
3,480 |
3,436 |
$0.00 |
| 90681 |
|
609 |
605 |
$0.00 |
| 90648 |
|
6,859 |
6,787 |
$0.00 |
| 90710 |
|
62 |
62 |
$0.00 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
59 |
55 |
$0.00 |
| 90672 |
|
44 |
43 |
$0.00 |
| 90713 |
|
12 |
12 |
$0.00 |
| 90380 |
|
14 |
13 |
$0.00 |